Featured Articles

NetSuite CRM Awarded Customers' Top Choice In UK's Software Satisfaction Awards 2008

NetSuite CRM Awarded Customers' Top Choice In UK's Software Satisfaction Awards 2008

Nov 10 2008 | comment(s)

LONDON and SAN MATEO, California, November 10 /PRNewswire/ --

- NetSuite Beats Salesforce.com and Sage for Best Enterprise CRM Software and Best Mid-Range CRM Software

NetSuite Inc. (NYSE: N), a leading vendor of on-demand, integrated business management software suites for mid-market enterprises and divisions of large companies, today announced that its U.K. customers have voted NetSuite CRM+ as best Enterprise Software and NetSuite CRM as the best Mid-Range Software in the customer relationship management (CRM) category of Sift Media's Software Satisfaction Awards 2008. NetSuite received the awards at a ceremony held Thursday, 30 October, in London. In each category, NetSuite beat a number of larger competitors, including salesforce.com and Sage.

Surgery To Be Made Sweeter - How A Doughnut-Shaped Sugar Molecule Offers Anaesthetists A New Way To Create Optimal Surgical Conditions

Surgery To Be Made Sweeter - How A Doughnut-Shaped Sugar Molecule Offers Anaesthetists A New Way To Create Optimal Surgical Conditions

Nov 10 2008 | comment(s)

WELWYN GARDEN CITY, England, November 10 /PRNewswire/ --

- Award-Winning UK Research Leads to First new Category of Drugs in Anaesthesia Medicine in the Last Two Decades

MGuard(TM), InspireMD's Novel Coronary Stent System, Was Celebrated By World Leading Interventional Cardiologists At The Transcatheter Cardiovascular Therapeutics (TCT) In Washington DC, USA, October 12-17 2008

MGuard(TM), InspireMD's Novel Coronary Stent System, Was Celebrated By World Leading Interventional Cardiologists At The Transcatheter Cardiovascular Therapeutics (TCT) In Washington DC, USA, October 12-17 2008

Nov 10 2008 | comment(s)

TEL AVIV, Israel, November 10 /PRNewswire/ -- InspireMD, developers of the novel MGuard(TM) coronary stent system, announced today that MGuard(TM) was successfully implanted in a complex lesion in a live case at the TCT '08. The procedure was performed by Dr. Dariusz Dudek and was broadcast from Krakow, Poland. Additionally, InspireMD's Breakfast Meeting Symposium A New Approach to Treating Thrombus Containing Lesions (ACS, AMI and SVG) was met with great enthusiasm and excitement. Some of the world's leading interventional cardiologists and opinion leaders were among the speakers at the MGuard(TM) symposium and included Alexandre Abizaid MD, Yaron Almagor MD, Carlo Di Mario MD, Martin Leon MD, and Chaim Lotan MD.

It's Not Only The Economy: It's The Kids' Survival (Stupid)

It's Not Only The Economy: It's The Kids' Survival (Stupid)

Nov 10 2008 | comment(s)

LONDON, November 10 /PRNewswire/ --

- Remembering the Two Great Wars, London Lawyer Sends Wake-Up Call to the World's Governments and Learned Bodies

International lawyer and world-affairs analyst, William Dunmore, (a grandfather and 2nd World War naval officer), has deep concerns for the children and future generations whose interests have been completely ignored in this troubled, money-mad world, where we are all sleep-walking into a crematorium.

Tomorrow he is, therefore, contacting all UNO, UNESCO and UNICEF permanent delegates and some 25,000 seats of learning by e-mail, with a unique Anti-Causal Plan For Rescuing The Young From The Dire Peril, namely, a Potential Third World War and Nuclear Doomsday.

Ancillary Revenues 2009: Airsavings' New Airline Program Increases Profits And Offers Travelers Added-Value From Their Frequent Flyer Miles

Ancillary Revenues 2009: Airsavings' New Airline Program Increases Profits And Offers Travelers Added-Value From Their Frequent Flyer Miles

Nov 10 2008 | comment(s)

PARIS, November 10 /PRNewswire/ --

Airsavings, the global leader in ancillary revenue development for low-cost airlines, has launched an innovative ancillary revenue platform called Privilege Outlet. The industry-first program attracts passengers through invitation-only online sales, featuring designer and name brand labels (Guess, Lacoste, Diesel etc.) with discounts of 30-70% off. Privilege Outlet, by providing passengers with an attractive, invitation-based option for mile accumulation and redemption, has created a powerful additional ancillary revenue stream for airlines while creating frequent flier programs that are wanted and viable again.

Learning Solutions Come Together

Learning Solutions Come Together

Nov 10 2008 | comment(s)

MUMBAI, India, November 10 /PRNewswire/ --

- Ashorne Hill and Tata Interactive Systems Join Hands to Enable Key Organisational Initiatives

Now both Ashorne Hill and Tata Interactive Systems, part of the $70 billion Tata Group, have come together to provide a range of bespoke Learning Solutions designed to help organisations address and support key business challenges.

Announcing the alliance, John Carson, Managing Director of Ashorne Hill said, The combination of Ashorne Hill's highly experienced Learning Development capability and Tata Interactive Systems' Learning Technology expertise will enable us to support our clients with solutions that enable employees to impact and deliver measurable results back into the business.

Blinkx Partners With People.com To Take Users Across The Red Carpet, Behind The Scenes, And Beyond

Blinkx Partners With People.com To Take Users Across The Red Carpet, Behind The Scenes, And Beyond

Nov 10 2008 | comment(s)

SAN FRANCISCO, November 10 /PRNewswire/ --

- Find out what's hot in Hollywood at blinkx.com

blinkx, the world's largest video search engine, today announced a content partnership with People.com, the leading celebrity news site. Under the terms of the agreement, blinkx has added People.com's high-quality, original video programming to its ever-expanding index.

Diagenic Announces Launch Of First Breast Cancer Gene-Expression Blood Test

Diagenic Announces Launch Of First Breast Cancer Gene-Expression Blood Test

Nov 10 2008 | comment(s)

OSLO and FOSTER CITY, California, November 10 /PRNewswire/ --

- India Chosen as First Commercial Market to Demonstrate Test's Potential for Rapid Uptake

DiaGenic ASA (OSL: DIAG) and Applied Biosystems Inc. (NYSE: ABI) today announced the launch of BCtect(TM), a blood-based test for early detection of breast cancer. The test searches for a unique gene expression signature identified by DiaGenic using a custom TaqMan(R) Array manufactured for DiaGenic by Applied Biosystems. India was chosen as the first country for the introduction of BCtect(TM) after successful completion of a large study in the country.

Raptor Pharmaceuticals To Collaborate With Centre Hospitalier Universitaire D'Angers For Phase II Clinical Trial In Huntington's Disease

Raptor Pharmaceuticals To Collaborate With Centre Hospitalier Universitaire D'Angers For Phase II Clinical Trial In Huntington's Disease

Nov 10 2008 | comment(s)

NOVATO, California, November 10 /PRNewswire/ --

Raptor Pharmaceuticals Corp. (Raptor or the Company) (OTC Bulletin Board: RPTP), today announced that the Company has entered into an agreement with the Centre Hospitalier Universitaire d'Angers (CHU d'Angers) of France to evaluate Raptor's proprietary delayed-release cysteamine bitartrate (DR Cysteamine) in a Phase II clinical trial in patients with Huntington's Disease (Huntington's). CHU d'Angers has received a grant from the Programme Hospitalier de Recherche Clinique - National, a program under the French Ministry of Health, to fund the two-year, multi-center Phase II clinical trial in Huntington's patients. Under the terms of the agreement, Raptor will provide clinical supplies of DR Cysteamine for the trial.

Amgen Foundation Launches 2.5 Million USD Undergraduate Research Programme In Europe

Amgen Foundation Launches 2.5 Million USD Undergraduate Research Programme In Europe

Nov 10 2008 | comment(s)

CAMBRIDGE, England, November 10 /PRNewswire/ --

- The European Hands-On Science Research Programme Brings the Amgen Foundation's Total Commitment to Amgen Scholars to 27.5 Million USD

The Amgen Foundation and the University of Cambridge, along with two other leading European universities, today announced the launch of Amgen Scholars Europe, a 2.5 million USD, two-year programme that will provide more than 100 selected undergraduate students from throughout Europe the opportunity to engage in a hands-on summer research experience under top academic scientists at three world class universities.

First Study In Real-Life Setting Confirms That Once-Monthly Mircera Keeps Haemoglobin Levels Within A Tight Range

First Study In Real-Life Setting Confirms That Once-Monthly Mircera Keeps Haemoglobin Levels Within A Tight Range

Nov 10 2008 | comment(s)

BASEL, Switzerland, November 10 /PRNewswire/ --

- Results Demonstrate Effective and Simplified Approach to Anaemia Management in Chronic Kidney Disease Patients on Dialysis

Interim study results from 90 renal centres in Germany confirm for the first time that in a real-life setting Mircera(R) maintains haemoglobin (Hb) levels within a narrow range when chronic kidney disease (CKD) patients receiving dialysis are switched to once-monthly Mircera from commonly used and frequently dosed erythropoiesis-stimulating agents (ESAs)(1).

Multimedia News Release: http://www.prnewswire.com/mnr/mircera/35922/

Marine Energy Market: Huge Potential For The UK

Marine Energy Market: Huge Potential For The UK

Nov 10 2008 | comment(s)

LONDON, November 10 /PRNewswire/ --

Global warming, energy security and rising oil prices have resuscitated the marine energy sector. Ocean energy is a predictable and abundant source of energy with the ability to supply approximately 10% of the world's electricity needs.

The value of worldwide electricity revenues from wave and tidal stream projects could ultimately be between pounds sterling 60bn (euro 77.40bn) and pounds sterling 190bn (euro 245.10bn) per year. The United Kingdom is a clear leader both in terms of activity and in terms of support to the sector. It possesses 50% of Europe's wave energy potential.

Making Biodiesel From Waste Using Nature's Own Chemical Plant

Making Biodiesel From Waste Using Nature's Own Chemical Plant

Nov 10 2008 | comment(s)

Petroleum is the feedstock for many products in the chemical industry but it is becoming increasingly expensive.  Renewable raw materials are an alternative but we quickly learned that, despite the beliefs of activists in the 1980s and 1990s, fuel from food was not a good idea.

Thanks to white industrial biotechnology, chemical substances can also be derived from waste products generated by the food industry, leftover biomass from agriculture and forestry, and residual materials. Researchers of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart are demonstrating how this biotechnical recycling works, using colza, whey and crab shells as examples.
Mutating Viruses To Death Using Forced Evolution

Mutating Viruses To Death Using Forced Evolution

Nov 10 2008 | comment(s)

It sounds like a science fiction movie: A killer contagion threatens the Earth, but scientists save the day with a designer drug that forces the virus to mutate itself out of existence. The killer disease? Still a fiction. The drug? It could become a reality thanks to a new study by Rice University bioengineers.

The study, which is available online and slated for publication in the journal Physical Review E, offers the most comprehensive mathematical analysis to date of the mechanisms that drive evolution in viruses and bacteria. Rather than focusing solely on random genetic mutations, as past analyses have, the study predicts exactly how evolution is affected by the exchange of entire genes and sets of genes.
Umbilical Cord Blood May Help Build New Heart Valves

Umbilical Cord Blood May Help Build New Heart Valves

Nov 10 2008 | comment(s)

Children with heart defects may someday receive perfectly-matched new heart valves built using stem cells from their umbilical cord blood, according to research presented at the American Heart Association's Scientific Sessions 2008.

When infants are born with malfunctioning heart valves that can't be surgically repaired, they rely on replacements from animal tissue, compatible human organ donations or artificial materials. These replacements are lifesaving, but don't grow and change shape as a child develops; so two or more surgeries may be needed to replace outgrown valves. The animal tissue may also stiffen over time as well and be less durable than a normal human valve.

Liquid Crystal Lubricants Reduce Friction, Save Lots Of Electricity

Liquid Crystal Lubricants Reduce Friction, Save Lots Of Electricity

Nov 10 2008 | comment(s)

We rarely think about the electricity impact of something like a conveyor belt at an airport.   When our luggage goes on , or we step on one, numerous gears with ball- and slide-bearings go to work.

The power consumption is tremendous, in the range of several gigawatt hours per annum. A substantial amount of this is lost through friction. In wind turbines and in cars, too, a percentage of the energy is spent on friction – reducing the efficiency factor accordingly. Novel lubricants that almost eliminate the effect of friction could be the answer. Once they have been set in motion, the bearings run and run and run.
Can This Pill Prevent Hearing Loss?

Can This Pill Prevent Hearing Loss?

Nov 10 2008 | comment(s)

About 10 million people in the United States alone—from troops returning from war to students with music blasting through headphones—are suffering from impairing noise-induced hearing loss. 

The rising trend is something that researchers and physicians at the University of Michigan Kresge Hearing Research Institute are hoping to reverse, with a cocktail of vitamins and the mineral magnesium that has shown promise as a possible way to prevent hearing loss caused by loud noises. The nutrients were successful in laboratory tests, and now researchers are testing whether humans will benefit as well.
Cytarabine For Ewing Sarcoma Doesn't Do Well In Clinical Trial

Cytarabine For Ewing Sarcoma Doesn't Do Well In Clinical Trial

Nov 10 2008 | comment(s)

Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults. Patients with relapsed or refractory Ewing sarcoma have a poor outcome with conventional therapies.

Cytarabine decreases the levels of a certain key protein in Ewing sarcoma cells and has demonstrated preclinical activity against Ewing sarcoma cell lines in the laboratory.   A new study published in Pediatric Blood&Cancer evaluated a phase II clinical trial of a potential new treatment approach for relapsed Ewing sarcoma using cytarabine.
India To The Moon: Chandrayaan-1 Now In Lunar Orbit

India To The Moon: Chandrayaan-1 Now In Lunar Orbit

Nov 10 2008 | comment(s)

Chandrayaan-1, the Indian Space Research Organisation’s (ISRO) lunar orbiter, was captured into orbit around the Moon on 8 November. One day later, the spacecraft performed a manoeuvre that lowered the closest point of its orbit down to 200 km from the Moon.
 
The spacecraft’s liquid-fuel propelled engine was fired at 12:21 CET (16:51 Indian Standard Time) when it was at a distance of about 500 km from the Moon. This reduced the spacecraft’s velocity, enabling the Moon’s gravitational field to capture Chandrayaan-1 into lunar orbit. In this configuration, the orbit’s point closest to the lunar surface was at 504 km and the spacecraft circled the Moon in 11 hours. 
At least Spore didn't confuse my kid

At least Spore didn't confuse my kid

Nov 10 2008 | comment(s)

OK, so you all know that Spore isn't based on how evolution actually works. There has been some concern that playing the game would cause players to develop a faulty understanding of evolution.

So I was pleasantly surprised tonight at my 8 year-old's response (completely unprompted, honest!) when I read her the following:

How does life change over time, and how did all those different forms of life come to be?... [Evolution] is the result of tiny changes adding up to bigger changes. These changes happen deep inside the cells of every living thing - in the genes, the instructions that make that living thing what it is. Genes are passed along from a parent to its offspring, and every living thing has its own unique combinations. Every individual is different. Just like you are different from your parents, every generation of living thing is different, in small ways, from the last.

Over time, these small differences add up. With enough time, they can add up to whole new forms of life.